BT200
- Generic Name
- BT200
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
BT200 (Rondoraptivon pegol) is a PEGylated anti-von Willebrand factor (VWF) aptamer targeted against the VWF A1 domain. It is under investigation for the treatment of von Willebrand disease and hemophilia A.
- Associated Conditions
- -
- Associated Therapies
- -
BT200 in Hereditary Bleeding Disorders
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 26
- Registration Number
- NCT04677803
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Band Therapeutics
- Target Recruit Count
- 112
- Registration Number
- NCT04103034
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath